Fig. 2
From: Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer
Progression of primary tumors in the LTLT breast cancer model (n = 5–6 mice). (A) Tumor growth over time via quantification of total photon flux from in vivo luminescence images. (B) Total photon flux of tumors at day 104 (end of study). (C) Box plot of percent tumor area measured by quantitative analysis of H&E staining over the gland area. Center line, median value; box, the 25th to 75th percentiles; whisker marks, the 5th and 95th percentiles. *P < 0.05, **P < 0.01, ***P < 0.001 by nonparametric Kruskal Wallis test. FUL, fulvestrant; LAS, lasofoxifene; PAL, palbociclib; SEM, standard error of the mean; Veh, vehicle